# Ataraxis AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ataraxis-ai

- Industry: Software
- Headquarters: New York, US
- Website: www.ataraxis.ai
- Total disclosed funding: $24M
- Latest round: Series A (Dec 20, 2024)
- Investors on record: 7

## About

Founded in 2023 and based in New York, US, Ataraxis AI, Inc. focuses on developing AI-driven diagnostic tools, including its flagship product, Ataraxis Breast, which evaluates cancer aggressiveness and treatment efficacy. Jan Witowski (CEO) and Krzysztof Geras are the co-founders of the company. In March 2025, Ataraxis AI, Inc. raised USD 20.4 million in series A funding led by new investor AIX Ventures, with participation from other new investors Floating Point, Thiel Bio, Founders Fund and Bertelsmann Investments. Other unspecified investors and returning investors Giant Ventures and Obvious Ventures also participated in the round. Ataraxis.ai specializes in advanced artificial intelligence solutions for cancer prognosis and treatment selection, particularly through its flagship product, Ataraxis Breast. This AI-native prognostic and predictive test integrates multi-modal data to assess the aggressiveness of breast cancer, predict risks of recurrence or death, and evaluate the efficacy of various treatment options for patients. Developed with clinical data from over 8,161 patients across 15 institutions, Ataraxis Breast identifies low- and high-risk patients. The technology leverages proprietary AI foundation models, such as Kestrel, trained on pathology slide images to uncover novel clinical and morphological insights that correlate strongly with patient outcomes. Ataraxis operates in multiple international markets, collaborating with renowned cancer centers and health systems globally to enhance cancer care through its solutions. Ataraxis.ai generates revenue primarily through partnerships and collaborations with healthcare institutions and cancer centers, focusing on the provision of its proprietary diagnostic tests. The company operates on a B2B model, entering into agreements with hospitals and clinics that utilize Ataraxis Breast and related services in their treatment protocols. Revenue is structured around diagnostic test fees, where institutions pay for each test conducted on their patient populations. The company will use the March 2025 funding to support the continuing development of offerings by expanding treatment selection capabilities within and beyond breast cancer as well as the development of next-generation AI foundation models.

## Funding rounds

- Series A, Dec 20, 2024, $20M — Founders Fund, Obvious, AIX Ventures, Giant Ventures, Floating Point, Bertelsmann Investments, Thiel Bio
- Seed, Jul 11, 2023, $4M — Obvious, Giant Ventures

## Investors

- Obvious (https://capitalatlas.ai/funds/obvious) — Seed, Series A
- Giant Ventures (https://capitalatlas.ai/funds/giant-ventures) — Seed, Series A
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series A
- AIX Ventures (https://capitalatlas.ai/funds/aix-ventures) — Series A
- Floating Point (https://capitalatlas.ai/funds/floating-point) — Series A
- Bertelsmann Investments (https://capitalatlas.ai/funds/bertelsmann-investments) — Series A
- Thiel Bio (https://capitalatlas.ai/funds/thiel-bio) — Series A